Hester Biosciences Limited — Investor Meet, 18-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Hester Biosciences reported strong Q4 financials with standalone revenue up 22% and PAT surging 174%. Full-year PAT increased 64%. The Poultry Healthcare division saw robust growth, up 41% in Q4 and 21% annually. While Animal Healthcare faced tender delays, Q4 execution improved, supplying 6.3 crore PPR doses. The company secured H9N2 Avian Influenza vaccine licenses and capitalized Fill-Finish & BSL-3 facilities. Net debt reduced to INR 70 Cr. Management aims for sustained poultry performance, a 50-50 revenue mix, disciplined growth, and operational efficiency, expressing confidence in long-term value from a strengthened foundation.